AHAA's ongoing advocacy in Washington DC protects the $3.5B hemp market from federal restrictions. Latest congressional developments and regulatory updates.

At a recent congressional hearing on cannabis policy, Rep. James Comer (R-KY) made one thing clear: the FDA’s refusal to regulate CBD is hurting farmers, entrepreneurs, and consumers. Without federal clarity, the hemp industry has been forced to operate in uncertainty, leaving responsible businesses at risk while opening the door for bad actors.

On September 16, 2025, Ohio lawmakers introduced Senate Bill 266 (SB 266), “Regards the sale and testing of intoxicating hemp products.”  If passed as written, this bill could severely restrict access to hemp-derived products in Ohio,  threatening small businesses, consumer choice, and patients who rely on these alternatives.